189 related articles for article (PubMed ID: 27669502)
1. Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.
Huang KC; Yang J; Ng MC; Ng SK; Welch WR; Muto MG; Berkowitz RS; Ng SW
Eur J Cancer; 2016 Nov; 67():152-163. PubMed ID: 27669502
[TBL] [Abstract][Full Text] [Related]
2. Expression of BAF57 in ovarian cancer cells and drug sensitivity.
Yamaguchi T; Kurita T; Nishio K; Tsukada J; Hachisuga T; Morimoto Y; Iwai Y; Izumi H
Cancer Sci; 2015 Apr; 106(4):359-66. PubMed ID: 25611552
[TBL] [Abstract][Full Text] [Related]
3. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.
Jiang L; Siu MK; Wong OG; Tam KF; Lu X; Lam EW; Ngan HY; Le XF; Wong ES; Monteiro LJ; Chan HY; Cheung AN
Clin Cancer Res; 2011 Nov; 17(21):6924-33. PubMed ID: 21926165
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells.
Weiner-Gorzel K; Dempsey E; Milewska M; McGoldrick A; Toh V; Walsh A; Lindsay S; Gubbins L; Cannon A; Sharpe D; O'Sullivan J; Murphy M; Madden SF; Kell M; McCann A; Furlong F
Cancer Med; 2015 May; 4(5):745-58. PubMed ID: 25684390
[TBL] [Abstract][Full Text] [Related]
5. Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.
Arsenic R; Braicu EI; Letsch A; Dietel M; Sehouli J; Keilholz U; Ochsenreither S
BMC Cancer; 2015 Oct; 15():784. PubMed ID: 26499264
[TBL] [Abstract][Full Text] [Related]
6. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.
Vaidyanathan A; Sawers L; Gannon AL; Chakravarty P; Scott AL; Bray SE; Ferguson MJ; Smith G
Br J Cancer; 2016 Aug; 115(4):431-41. PubMed ID: 27415012
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP.
Xie X; Bartholomeusz C; Ahmed AA; Kazansky A; Diao L; Baggerly KA; Hortobagyi GN; Ueno NT
Mol Cancer Ther; 2013 Jun; 12(6):1099-111. PubMed ID: 23543364
[TBL] [Abstract][Full Text] [Related]
8. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
Xu Y; Zhang J; Wu J; Zhong S; Li H
Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.
Huang L; Ao Q; Zhang Q; Yang X; Xing H; Li F; Chen G; Zhou J; Wang S; Xu G; Meng L; Lu Y; Ma D
J Cancer Res Clin Oncol; 2010 Mar; 136(3):447-56. PubMed ID: 19760195
[TBL] [Abstract][Full Text] [Related]
11. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract][Full Text] [Related]
12. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance.
Fu Y; Hu D; Qiu J; Xie X; Ye F; Lu WG
Int J Gynecol Cancer; 2011 Apr; 21(3):439-44. PubMed ID: 21436692
[TBL] [Abstract][Full Text] [Related]
14. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.
Horio M; Kato T; Mii S; Enomoto A; Asai M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
Cancer Med; 2012 Oct; 1(2):218-29. PubMed ID: 23342271
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.
Liu X; Gao Y; Shen J; Yang W; Choy E; Mankin H; Hornicek FJ; Duan Z
Mol Cancer Ther; 2016 Jul; 15(7):1691-701. PubMed ID: 27207777
[TBL] [Abstract][Full Text] [Related]
16. Survivin siRNA increases sensitivity of primary cultures of ovarian cancer cells to paclitaxel.
Kar R; Palanichamy JK; Banerjee A; Chattopadhyay P; Jain SK; Singh N
Clin Transl Oncol; 2015 Sep; 17(9):737-42. PubMed ID: 26033427
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
19. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
20. Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance.
Zhang J; Zhao J; Zhang W; Liu G; Yin D; Li J; Zhang S; Li H
Int J Gynecol Cancer; 2012 Nov; 22(9):1450-6. PubMed ID: 23051955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]